Phonons in MgB2 by Polarized Raman Scattering on Single Crystals

The paper presents detailed Raman scattering study of the unusually broad E2g phonon mode in MgB2 crystal. For the first time, it is shown by the polarized Raman scattering on few-micron-size crystallites with natural faces that the observed broad Raman feature really does obey the selection rules of an E2g mode. Raman spectra on high quality polycrystalline superconducting MgB2 wires reveal a very symmetric E2g phonon line near 615 1/cm with the room temperature linewidth of 260 1/cm only. Additional scattering of different polarization dependence, observed in certain crystallites is interpreted as weighted phonon density of states induced by lattice imperfections.Comment: 4 pages + 7 figure

Pressure-induced changes in the optical properties of quasi-one-dimensional β\beta-Na0.33_{0.33}V2_2O5_5

The pressure-induced changes in the optical properties of $\beta$-Na$_{0.33}$V$_2$O$_5$ single crystals at room temperature were studied by polarization-dependent Raman and far-infrared reflectivity measurements under high pressure. From the changes in the Raman- and infrared-active phonon modes in the pressure range 9 - 12 GPa a transfer of charge between the different V sites can be inferred. The importance of electron-phonon coupling in the low-pressure regime is discussed.Comment: 7 pages, 5 figure

LiBC by polarized Raman spectroscopy: Evidence for lower crystal symmetry ?

The paper presents polarized Raman scattering study on a few-micron-size crystallite of LiBC with natural faces. The experiment on as grown sample has revealed a four lattice modes with frequencies at 1276 cm^-1, 830 cm^-1, 546 cm^-1 and 170 cm^-1, respectively. The number of observed Raman lines and their selection rules are incompatible with the assumed D6h symmetry. The modes at 1276 cm^-1 and 170 cm^-1 correspond to the expected Raman active modes. In contrast with the superconducting compound MgB2, the B-C bond stretching mode (at 1276 cm^-1) has rather small damping. The two "forbidden" modes (at 830 cm^-1 and 546 cm^-1) disappeared after subsequent thermal treatment.Comment: 4 pages, LaTeX, complementary experimental resul

Micro-Raman Mapping of 3C-SiC Thin Films Grown by Solid–Gas Phase Epitaxy on Si (111)

A series of 3C-SiC films have been grown by a novel method of solid–gas phase epitaxy and studied by Raman scattering and scanning electron microscopy (SEM). It is shown that during the epitaxial growth in an atmosphere of CO, 3C-SiC films of high crystalline quality, with a thickness of 20 nm up to few hundreds nanometers can be formed on a (111) Si wafer, with a simultaneous growth of voids in the silicon substrate under the SiC film. The presence of these voids has been confirmed by SEM and micro-Raman line-mapping experiments. A significant enhancement of the Raman signal was observed in SiC films grown above the voids, and the mechanisms responsible for this enhancement are discussed

Lattice modes and the Jahn-Teller ferroelectric transition of GaV4S8

Crystal of GaV4S8, a multiferroic system hosting a Neel-type skyrmion lattice phase, has been investigated by polarized Raman and IR spectroscopy above and below the ferroelectric phase transition. Counts of the observed IR and Raman-active modes belonging to distinct irreducible representations agree quite well with group-theory predictions. Phonon spectra are assigned and interpreted with the aid of ab initio calculations of the phonon spectra in the ferroelectric phase. Results allow appreciation of phonon frequencies of the modes involved in Jahn-Teller distortion and their contribution to the spontaneous polarizationclos

Boxnep - модульный подводный робот перспективных технологий

The article discusses the relevance of the underwater vehicles are able to solve a wide range of problems. The decision puts in a basis of the research is designing a modular underwater robot. It allows to make a mounting of various equipment and testing it in the water medium. The paper deals with the concept of the robot and its characteristics

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Background: Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods: In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1:1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1·3 mg/m2; intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat population. All participants who received at least one dose of study drug were included in the safety analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary endpoint are presented. The trial is registered at ClinicalTrials.gov, number NCT01568866. Findings: Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib group; 465 to the bortezomib group). Median follow-up was 11·9 months (IQR 9·3-16·1) in the carfilzomib group and 11·1 months (8·2-14·3) in the bortezomib group. Median progression-free survival was 18·7 months (95% CI 15·6-not estimable) in the carfilzomib group versus 9·4 months (8·4-10·4) in the bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0·53 [95% CI 0·44-0·65]; p<0·0001). On-study death due to adverse events occurred in 18 (4%) of 464 patients in the carfilzomib group and in 16 (3%) of 465 patients in the bortezomib group. Serious adverse events were reported in 224 (48%) of 463 patients in the carfilzomib group and in 162 (36%) of 456 patients in the bortezomib group. The most frequent grade 3 or higher adverse events were anaemia (67 [14%] of 463 patients in the carfilzomib group vs 45 [10%] of 456 patients in the bortezomib group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia (39 [8%] vs 43 [9%]), and pneumonia (32 [7%] vs 36 [8%]). Interpretation: For patients with relapsed or refractory multiple myeloma, carfilzomib with dexamethasone could be considered in cases in which bortezomib with dexamethasone is a potential treatment option. Funding: Onyx Pharmaceuticals, Inc., an Amgen subsidiary